健民集團(600976.SH):上半年淨利同比升2.22%至5719.66萬元
格隆匯 8 月 12日丨健民集團(600976.SH)公佈半年報,2020年上半年,“三醫聯動改革”持續深入推進,集中帶量採購常態化,一致性評價加速、用藥方式及支付方式改革等,醫藥企業承壓;國家鼓勵創新藥物發展、醫療衞生投入持續加大等給醫藥行業也帶來發展機遇。面對醫藥行業變化,公司持續推進精益生產、提高產品品質,創新營銷模式、加大品牌推廣,努力實現公司經營業績的穩定,上半年營業收入10.27億元,同比下降7.61%,其中工業收入5.11億元,同比下降9.61%,商業收入5.17億元,同比下降5.55%,公司工業收入的下降主要是受疫情影響,3月份才陸續恢復生產與銷售。歸屬於上市公司股東的淨利潤5719.66萬元,同比增長2.2%,淨利潤的增長主要來自於公司主導產品龍牡收入增長及參股公司健民大鵬藥業業績增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.